ðə sˈeɪm ɡɹˈuːp ɪn ˈɪɾəli fˈaʊnd ðætðə kˌɑːmbᵻnˈeɪʃən ʌv ɪmˈætɪnˌɪb ænd sˈɪɹəlˌɪməs kˈɔːzd ɐ ɹᵻspˈɑːns ɪn sˈɛvɹəl pˈeɪʃənts hˌuːz tˈuːmɚz pɹəɡɹˈɛst ˌɔn ɪmˈætɪnˌɪb ɐlˈoʊn.
The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose tumors progressed on imatinib alone.